about
Novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2): crystal structures, biochemical activity, and intracellular effects of imidazoacridin-6-onesIn Silico Screening Reveals Structurally Diverse, Nanomolar Inhibitors of NQO2 That Are Functionally Active in Cells and Can Modulate NF- B SignalingSite and strain-specific variation in gut microbiota profiles and metabolism in experimental miceZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity.Contribution of HIF-1 and drug penetrance to oxaliplatin resistance in hypoxic colorectal cancer cells.Glucocorticoid receptor over-expression promotes human small cell lung cancer apoptosis in vivo and thereby slows tumor growth.Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport.Antiangiogenic, bioreductive and gene therapy approaches to the treatment of hypoxic tumours.Identification and functional analysis of SKA2 interaction with the glucocorticoid receptor.A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor modelsCombining bioreductive drugs and radiation for the treatment of solid tumors.Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.Hypoxia in tumors: molecular targets for anti-cancer therapeutics.Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth.Expression of the proapoptotic protein Bid is an adverse prognostic factor for radiotherapy outcome in carcinoma of the cervix.Combination of photodynamic therapy (PDT) and melphalan in experimental tumors.Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance.Dissecting the role of multiple reductases in bioactivation and cytotoxicity of the antitumor agent 2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone (RH1)17beta-Oestradiol treatment modulates nitric oxide synthase activity in MDA231 tumour with implications on growth and radiation response.Investigation of radiosensitivity gene signatures in cancer cell lines.Guidelines for preclinical and early phase clinical assessment of novel radiosensitisersEmerging opportunities for the combination of molecularly targeted drugs with radiotherapy.Clinical development of new drug-radiotherapy combinations.A synthetic approach to novel carvotacetone and antheminone analogues with anti-tumour activity.Acetylation mediated by the p300/CBP-associated factor determines cellular energy metabolic pathways in cancer.Inhibitors of NQO1: identification of compounds more potent than dicoumarol without associated off-target effects.Spectrophotometric analysis of nucleic acids: oxygenation-dependent hyperchromism of DNA.In vivo activation of the hypoxia-targeted cytotoxin AQ4N in human tumor xenografts.The impact of intracellular generation of nitric oxide on the radiation response of human tumor cells.Effects of cytokine-induced macrophages on the response of tumor cells to banoxantrone (AQ4N).PCAF is an HIF-1alpha cofactor that regulates p53 transcriptional activity in hypoxia.Overexpression of cytochrome P450 NADPH reductase sensitises MDA 231 breast carcinoma cells to 5-fluorouracil: possible mechanisms involved.Chemical synthesis and biological evaluation of a NAD(P)H:quinone oxidoreductase-1 targeted tripartite quinone drug delivery system.Coumarin-based inhibitors of human NAD(P)H:quinone oxidoreductase-1. Identification, structure-activity, off-target effects and in vitro human pancreatic cancer toxicity.The two common polymorphic forms of human NRH-quinone oxidoreductase 2 (NQO2) have different biochemical properties.Reversing hypoxic cell chemoresistance in vitro using genetic and small molecule approaches targeting hypoxia inducible factor-1.Tirapazamine administered as a neoadjuvant to radiotherapy reduces metastatic dissemination.Hypoxia-inducible factor 1alpha expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix.Construction and characterization of multiple human colon cancer cell lines for inducibly regulated gene expression.The importance of DT-diaphorase and hypoxia in the cytotoxicity of RH1 in human breast and non-small cell lung cancer cell lines.
P50
Q27671889-59ADEBB9-A587-4D37-8D7E-5C69B0231D9CQ27675614-224EF4A7-AAD9-48B6-AA80-DFA968DDBF3EQ28472438-C289A443-A1C2-4674-A5C6-B1EA0A1117B3Q33210440-B1E0A375-E85C-4B73-8A37-DB3DC636E727Q33503545-95D6AE5A-0F4D-457B-B779-06179CAFF3B2Q33689201-E1A7CBD1-7CFC-4428-8675-050E27BC236DQ34646307-86F97583-3A4B-4CBD-86B3-0FE7983987CBQ34673937-1DC671F6-32D3-4541-902E-3C9FF8CAE2EFQ34789563-63FFF454-123F-4510-9826-F40336C1A2FAQ34853959-480A13DE-83E8-4BA1-85D2-EDE5E88891E8Q35042092-FCBE6D2C-477E-40D8-8452-9A37D5403203Q35329755-E3C55C69-818F-4F8E-B600-60CDC2CA8A5AQ35974228-C5780B90-9529-4F3E-9AA5-1916D5F6C1B1Q36301943-70E35C8F-1AA9-4207-AF0C-F4219678917AQ36617005-80C79F36-9EDC-46A1-AACB-4AD0A899DEFFQ36731494-A3C6DA61-08DE-41A1-A027-47F497C508F2Q37011260-4C01DA6A-D3CB-4611-86E5-CFE8E3F2D842Q37033761-BDD4B00F-E1B7-4F38-9202-81DF5B47C393Q37352661-BD30396F-4CA3-40E2-9185-F6FB2FBBA9ADQ37505655-8E5B4E03-5A6F-4540-88BA-074AD556A046Q37902873-8D1DEDF4-4F67-4AD9-A6E9-754B8D527E61Q38193943-C176C54D-383B-4E28-BE45-41A362049626Q38849191-97E48404-504A-4A63-8B9A-6E5996387FDAQ39111398-B297163A-2622-4514-8254-870AE2B07A83Q39165302-D643D861-CC75-4853-A21C-4168D8FCDAD9Q39640846-6CC34A8A-8849-4FB8-8176-0565331A92BCQ39737549-8118416E-57C8-451D-A517-CB2A0CC42670Q39765512-ADB15E74-56FC-4646-B513-E684FFAE34FFQ39828677-E8F005CF-44C9-45A3-B21C-2F3BC9F76D7EQ39852629-E45CF605-49BE-477E-82A2-4EEB01E36FEFQ39968880-57BA0F97-6FED-44A8-8029-714CD76D7F6EQ40025819-29771789-1040-4857-8608-65D69DE3A13EQ40033890-C59BCAD0-FA44-4B0D-AE27-05FCB34D3FA0Q40052618-A9AABD56-AF8F-4265-9A0C-B3921CD603F3Q40296515-5C29AE35-E76A-4B36-B5DE-E8C9E993A616Q40357279-285E24C7-C72E-4425-9ABA-ECA08728739AQ40414385-74E11B79-6137-485C-8D05-05D53C553DEAQ40458180-844F6DC9-DCBC-4009-A2C5-B6D3B41B7380Q40466207-42387FD7-9365-4391-97C7-BDA259A1A5A4Q40565644-CA7BEB28-2ED5-46FF-AD76-2703B6D43C22
P50
description
onderzoeker
@nl
researcher
@en
researcher
@en-gb
հետազոտող
@hy
name
Ian J Stratford
@ast
Ian J Stratford
@en
Ian J Stratford
@en-gb
Ian J Stratford
@es
Ian J Stratford
@nl
Ian J Stratford
@sl
type
label
Ian J Stratford
@ast
Ian J Stratford
@en
Ian J Stratford
@en-gb
Ian J Stratford
@es
Ian J Stratford
@nl
Ian J Stratford
@sl
prefLabel
Ian J Stratford
@ast
Ian J Stratford
@en
Ian J Stratford
@en-gb
Ian J Stratford
@es
Ian J Stratford
@nl
Ian J Stratford
@sl
P106
P1153
7004547474
P31
P496
0000-0002-5222-4765